MiR-221, miR-320a, miR133a, and miR-133b as potential biomarkers in leiomyosarcoma
BackgroundLeiomyosarcoma is an aggressive tumor with a high rate of distant metastasis and poor prognosis. No standardized biomarkers are available to assess early diagnosis or monitoring during the clinical course. MicroRNAs (miRNAs) function in modulating a multitude of targets and are involved in...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1577859/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849705514570612736 |
|---|---|
| author | Mst Nasrin Akhtar Mst Nasrin Akhtar Annabell Walter Annabell Walter Kathrin Katenkamp Kathrin Katenkamp Yuan Chen Yuan Chen Thomas Lehmann Thomas Lehmann Wolfram Weschenfelder Wolfram Weschenfelder Christian Spiegel Christian Spiegel Matthias Vogt Gunther O. Hofmann Gunther O. Hofmann Andreas Hochhaus Andreas Hochhaus Nikolaus Gaßler Nikolaus Gaßler Joachim H. Clement Joachim H. Clement Karin G. Schrenk Karin G. Schrenk |
| author_facet | Mst Nasrin Akhtar Mst Nasrin Akhtar Annabell Walter Annabell Walter Kathrin Katenkamp Kathrin Katenkamp Yuan Chen Yuan Chen Thomas Lehmann Thomas Lehmann Wolfram Weschenfelder Wolfram Weschenfelder Christian Spiegel Christian Spiegel Matthias Vogt Gunther O. Hofmann Gunther O. Hofmann Andreas Hochhaus Andreas Hochhaus Nikolaus Gaßler Nikolaus Gaßler Joachim H. Clement Joachim H. Clement Karin G. Schrenk Karin G. Schrenk |
| author_sort | Mst Nasrin Akhtar |
| collection | DOAJ |
| description | BackgroundLeiomyosarcoma is an aggressive tumor with a high rate of distant metastasis and poor prognosis. No standardized biomarkers are available to assess early diagnosis or monitoring during the clinical course. MicroRNAs (miRNAs) function in modulating a multitude of targets and are involved in tumorigenesis, cancer progression, and metastasis. This study was designed to evaluate miR-221, miR-320a, miR-133a, and miR-133b as potential biomarkers in leiomyosarcoma.Materials and methodsThe expression levels of miR-221, miR-320a, miR-133a, and miR-133b as well as their target mRNAs CDKN1B, TGFBR1, and IGF1R were assessed by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) in tissue samples from 33 patients with leiomyosarcoma. Wilcoxon test, Kruskal-Wallis test, Mann-Whitney test as well as Spearman-Rho-test were used for statistical analysis. Receiver operating characteristic (ROC) analyses were performed to discriminate metastatic risk of local and primary tumors in correlation to miR-221, miR-320a, miR-133a, and miR-133b.Results and discussionThe expression levels of miR-221, miR-320a, and miR-133a were significantly upregulated in leiomyosarcoma tumor tissue compared to adjacent non-tumor tissue (p = 0.003 for miR-221, p = 0.006 for miR-320a, and p = 0.044 for miR-133a respectively). The target mRNAs CDKN1B, TGFBR1, and IGF1R in 25 leiomyosarcoma tumor tissues were not significantly deregulated. There was no significant upregulation in primary tumors and metastases compared to local tumors for miR-221, miR-320a, miR-133a, and miR-133b. ROC curves of miRNA-221, miR-320a, miR-133a, and miR-133b to predict metastatic risk at initial presentation of the tumor, comparing non-metastasizing and metastasizing leiomyosarcomas, demonstrated no significant levels.ConclusionmiR-221, miR-320a, and miR-133a were significantly upregulated in leiomyosarcoma tumor tissue as compared to adjacent non-tumor tissue. There was no significant difference in miRNA expression and ROC curves in primary tumors as compared to local tumors. While not statistically significant, ROC curve of miR-133b suggests a potential role in predicting metastatic risk, warranting subsequent analysis. This study provides evidence for further evaluation of miR-221, miR-320a, miR-133a, and miR-133b as biomarkers in primary diagnosis and assessment of metastatic risk in leiomyosarcoma. |
| format | Article |
| id | doaj-art-16c83ea6be7d4ae9ae62c5c19291448a |
| institution | DOAJ |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-16c83ea6be7d4ae9ae62c5c19291448a2025-08-20T03:16:26ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-06-011510.3389/fonc.2025.15778591577859MiR-221, miR-320a, miR133a, and miR-133b as potential biomarkers in leiomyosarcomaMst Nasrin Akhtar0Mst Nasrin Akhtar1Annabell Walter2Annabell Walter3Kathrin Katenkamp4Kathrin Katenkamp5Yuan Chen6Yuan Chen7Thomas Lehmann8Thomas Lehmann9Wolfram Weschenfelder10Wolfram Weschenfelder11Christian Spiegel12Christian Spiegel13Matthias Vogt14Gunther O. Hofmann15Gunther O. Hofmann16Andreas Hochhaus17Andreas Hochhaus18Nikolaus Gaßler19Nikolaus Gaßler20Joachim H. Clement21Joachim H. Clement22Karin G. Schrenk23Karin G. Schrenk24Abteilung für Hämatologie und Internistische Onkologie, Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, GermanyMitteldeutsches Krebszentrum, Standort Jena, Jena, GermanyAbteilung für Hämatologie und Internistische Onkologie, Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, GermanyMitteldeutsches Krebszentrum, Standort Jena, Jena, GermanyMitteldeutsches Krebszentrum, Standort Jena, Jena, GermanyInstitut für Rechtsmedizin, Sektion Pathologie, Universitätsklinikum Jena, Jena, GermanyMitteldeutsches Krebszentrum, Standort Jena, Jena, GermanyInstitut für Rechtsmedizin, Sektion Pathologie, Universitätsklinikum Jena, Jena, GermanyMitteldeutsches Krebszentrum, Standort Jena, Jena, GermanyInstitut für Medizinische Statistik, Informatik und Datenwissenschaften, Universitätsklinikum Jena, Jena, GermanyMitteldeutsches Krebszentrum, Standort Jena, Jena, GermanyKlinik für Unfall-, Hand- und Wiederherstellungschirurgie, Universitätsklinikum Jena, Jena, GermanyMitteldeutsches Krebszentrum, Standort Jena, Jena, GermanyKlinik für Unfall-, Hand- und Wiederherstellungschirurgie, Universitätsklinikum Jena, Jena, GermanyKlinik im Medizentrum PartGmbB, Erlangen, GermanyMitteldeutsches Krebszentrum, Standort Jena, Jena, GermanyKlinik für Unfall-, Hand- und Wiederherstellungschirurgie, Universitätsklinikum Jena, Jena, GermanyAbteilung für Hämatologie und Internistische Onkologie, Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, GermanyMitteldeutsches Krebszentrum, Standort Jena, Jena, GermanyMitteldeutsches Krebszentrum, Standort Jena, Jena, GermanyInstitut für Rechtsmedizin, Sektion Pathologie, Universitätsklinikum Jena, Jena, GermanyAbteilung für Hämatologie und Internistische Onkologie, Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, GermanyMitteldeutsches Krebszentrum, Standort Jena, Jena, GermanyAbteilung für Hämatologie und Internistische Onkologie, Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, GermanyMitteldeutsches Krebszentrum, Standort Jena, Jena, GermanyBackgroundLeiomyosarcoma is an aggressive tumor with a high rate of distant metastasis and poor prognosis. No standardized biomarkers are available to assess early diagnosis or monitoring during the clinical course. MicroRNAs (miRNAs) function in modulating a multitude of targets and are involved in tumorigenesis, cancer progression, and metastasis. This study was designed to evaluate miR-221, miR-320a, miR-133a, and miR-133b as potential biomarkers in leiomyosarcoma.Materials and methodsThe expression levels of miR-221, miR-320a, miR-133a, and miR-133b as well as their target mRNAs CDKN1B, TGFBR1, and IGF1R were assessed by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) in tissue samples from 33 patients with leiomyosarcoma. Wilcoxon test, Kruskal-Wallis test, Mann-Whitney test as well as Spearman-Rho-test were used for statistical analysis. Receiver operating characteristic (ROC) analyses were performed to discriminate metastatic risk of local and primary tumors in correlation to miR-221, miR-320a, miR-133a, and miR-133b.Results and discussionThe expression levels of miR-221, miR-320a, and miR-133a were significantly upregulated in leiomyosarcoma tumor tissue compared to adjacent non-tumor tissue (p = 0.003 for miR-221, p = 0.006 for miR-320a, and p = 0.044 for miR-133a respectively). The target mRNAs CDKN1B, TGFBR1, and IGF1R in 25 leiomyosarcoma tumor tissues were not significantly deregulated. There was no significant upregulation in primary tumors and metastases compared to local tumors for miR-221, miR-320a, miR-133a, and miR-133b. ROC curves of miRNA-221, miR-320a, miR-133a, and miR-133b to predict metastatic risk at initial presentation of the tumor, comparing non-metastasizing and metastasizing leiomyosarcomas, demonstrated no significant levels.ConclusionmiR-221, miR-320a, and miR-133a were significantly upregulated in leiomyosarcoma tumor tissue as compared to adjacent non-tumor tissue. There was no significant difference in miRNA expression and ROC curves in primary tumors as compared to local tumors. While not statistically significant, ROC curve of miR-133b suggests a potential role in predicting metastatic risk, warranting subsequent analysis. This study provides evidence for further evaluation of miR-221, miR-320a, miR-133a, and miR-133b as biomarkers in primary diagnosis and assessment of metastatic risk in leiomyosarcoma.https://www.frontiersin.org/articles/10.3389/fonc.2025.1577859/fullmiRNAmiR-221miR-320amiR-133amiR-133bsarcoma |
| spellingShingle | Mst Nasrin Akhtar Mst Nasrin Akhtar Annabell Walter Annabell Walter Kathrin Katenkamp Kathrin Katenkamp Yuan Chen Yuan Chen Thomas Lehmann Thomas Lehmann Wolfram Weschenfelder Wolfram Weschenfelder Christian Spiegel Christian Spiegel Matthias Vogt Gunther O. Hofmann Gunther O. Hofmann Andreas Hochhaus Andreas Hochhaus Nikolaus Gaßler Nikolaus Gaßler Joachim H. Clement Joachim H. Clement Karin G. Schrenk Karin G. Schrenk MiR-221, miR-320a, miR133a, and miR-133b as potential biomarkers in leiomyosarcoma Frontiers in Oncology miRNA miR-221 miR-320a miR-133a miR-133b sarcoma |
| title | MiR-221, miR-320a, miR133a, and miR-133b as potential biomarkers in leiomyosarcoma |
| title_full | MiR-221, miR-320a, miR133a, and miR-133b as potential biomarkers in leiomyosarcoma |
| title_fullStr | MiR-221, miR-320a, miR133a, and miR-133b as potential biomarkers in leiomyosarcoma |
| title_full_unstemmed | MiR-221, miR-320a, miR133a, and miR-133b as potential biomarkers in leiomyosarcoma |
| title_short | MiR-221, miR-320a, miR133a, and miR-133b as potential biomarkers in leiomyosarcoma |
| title_sort | mir 221 mir 320a mir133a and mir 133b as potential biomarkers in leiomyosarcoma |
| topic | miRNA miR-221 miR-320a miR-133a miR-133b sarcoma |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1577859/full |
| work_keys_str_mv | AT mstnasrinakhtar mir221mir320amir133aandmir133baspotentialbiomarkersinleiomyosarcoma AT mstnasrinakhtar mir221mir320amir133aandmir133baspotentialbiomarkersinleiomyosarcoma AT annabellwalter mir221mir320amir133aandmir133baspotentialbiomarkersinleiomyosarcoma AT annabellwalter mir221mir320amir133aandmir133baspotentialbiomarkersinleiomyosarcoma AT kathrinkatenkamp mir221mir320amir133aandmir133baspotentialbiomarkersinleiomyosarcoma AT kathrinkatenkamp mir221mir320amir133aandmir133baspotentialbiomarkersinleiomyosarcoma AT yuanchen mir221mir320amir133aandmir133baspotentialbiomarkersinleiomyosarcoma AT yuanchen mir221mir320amir133aandmir133baspotentialbiomarkersinleiomyosarcoma AT thomaslehmann mir221mir320amir133aandmir133baspotentialbiomarkersinleiomyosarcoma AT thomaslehmann mir221mir320amir133aandmir133baspotentialbiomarkersinleiomyosarcoma AT wolframweschenfelder mir221mir320amir133aandmir133baspotentialbiomarkersinleiomyosarcoma AT wolframweschenfelder mir221mir320amir133aandmir133baspotentialbiomarkersinleiomyosarcoma AT christianspiegel mir221mir320amir133aandmir133baspotentialbiomarkersinleiomyosarcoma AT christianspiegel mir221mir320amir133aandmir133baspotentialbiomarkersinleiomyosarcoma AT matthiasvogt mir221mir320amir133aandmir133baspotentialbiomarkersinleiomyosarcoma AT guntherohofmann mir221mir320amir133aandmir133baspotentialbiomarkersinleiomyosarcoma AT guntherohofmann mir221mir320amir133aandmir133baspotentialbiomarkersinleiomyosarcoma AT andreashochhaus mir221mir320amir133aandmir133baspotentialbiomarkersinleiomyosarcoma AT andreashochhaus mir221mir320amir133aandmir133baspotentialbiomarkersinleiomyosarcoma AT nikolausgaßler mir221mir320amir133aandmir133baspotentialbiomarkersinleiomyosarcoma AT nikolausgaßler mir221mir320amir133aandmir133baspotentialbiomarkersinleiomyosarcoma AT joachimhclement mir221mir320amir133aandmir133baspotentialbiomarkersinleiomyosarcoma AT joachimhclement mir221mir320amir133aandmir133baspotentialbiomarkersinleiomyosarcoma AT karingschrenk mir221mir320amir133aandmir133baspotentialbiomarkersinleiomyosarcoma AT karingschrenk mir221mir320amir133aandmir133baspotentialbiomarkersinleiomyosarcoma |